Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase.

Autor: Kikuchi, Shohei, Nabe, Yoshimi, Horaguchi, Ryusuke, Minemura, Tomoki, Murakami, Jun, Noguchi, Akira, Takagi, Kohji, Kamihara, Yusuke, Wada, Akinori, Fujihira, Takuma, Sato, Tsutomu

Publikováno v: International Cancer Conference Journal; Oct2024, Vol. 13 Issue 4, p488-492, 5p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options.

Autor: Kikuchi S; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan., Muro M; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan.; Center for Medical Residency Training, Toyama University Hospital, Toyama, Japan., Kamihara Y; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan., Wada A; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan., Murakami J; Division of Transfusion Medicine and Cell Therapy, Toyama University Hospital, Toyama, Japan., Nabe Y; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan., Minemura T; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan., Sato T; Department of Hematology, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0152 Japan.

Publikováno v: International cancer conference journal [Int Cancer Conf J] 2022 Oct 28; Vol. 12 (1), pp. 69-74. Date of Electronic Publication: 2022 Oct 28 (Print Publication: 2023).